01358 PW MEDTECH
- 1.000
- 0.0000.00%
PW MEDTECH News
PW Medtech Plans Subsidiary Spin-Off for Market Growth
PW Medtech Discloses New Address for Principal Share Registrar, Transfer Office
PW Medtech (HKG:1358) said the address of Ocorian Trust (Cayman), the principal share registrar and transfer office of the company, has been changed to Windward 3, Regatta Office Park, PO Box 1350, Gr
PW Medtech Considers Spinning-Off Sichuan Ruijian Medical
PW Medtech (HKG:1358) is considering the proposed spin-off of its unit, Sichuan Ruijian Medical, via a separate "National Equities Exchange and Quotations" (NEEQS) quotation and a following listing on
PW Medtech: Sichuan Ruijian Medical IPO Likely in 2H
PW Medtech: Sichuan Ruijian Medical IPO Likely in 2H
PW Medtech Planning IPO of Non-Wholly Owned Unit Sichuan Ruijian Medical Planning IPO
PW Medtech Planning IPO of Non-Wholly Owned Unit Sichuan Ruijian Medical Planning IPO
PricewaterhouseCoopers (01358): Proposals are being considered to split off Sichuan Ruijian Medical for independent listing in the National Small and Medium Enterprises Share Transfer System and then listing on the Beijing Stock Exchange
PricewaterhouseCoopers (01358) issued an announcement. The company is considering a proposal to split its non-wholly-owned subsidiary, Sichuan Ruijian Medical to independently list (not issue new shares) in the national SME share transfer system, and then list it on the Beijing Stock Exchange according to market conditions at the time and its strategic development needs.
Express News | Everbright Securities: Demand for medical devices and scientific instruments is expected to expand
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
普華和順：年報2023
PW MEDTECH To Go Ex-Dividend On July 4th, 2024 With 0.0495 HKD Dividend Per Share
April 1st - $PW MEDTECH(01358.HK)$ is trading ex-dividend on July 4th, 2024. Shareholders of record on July 5th, 2024 will receive 0.0495 HKD dividend per share on July 26th, 2024. The ex-dividend
PricewaterhouseCoopers (01358) will pay a final dividend of HK4.95 cents per share on July 26
PricewaterhouseCoopers (01358) announced that it will pay a final dividend of HK4.95 cents per share on July 26, 2024...
PW MEDTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
PricewaterhouseCoopers (01358.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 PricewaterhouseCoopers (01358.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday). The agenda includes approving the publication of the comprehensive annual results announcement of the company and its subsidiaries for the year ended December 31, 2023, and considering the payment of a final dividend proposal (if any).
PW MEDTECH: DATE OF BOARD MEETING
Changes in Hong Kong stocks | PricewaterhouseCoopers (01358) surged more than 10% after earnings, and is expected to achieve annual net profit of about $192 million to $215 million, up 49% to 67% year-on-year
The Zhitong Finance App learned that PricewaterhouseCoopers (01358) surged more than 10% to a new high. As of press release, it had risen 10.84% to HK$0.92, with a turnover of HK$1.17 million. According to the news, Pratt & Wah Heshun announced that the Group is expected to obtain a net profit of approximately RMB 192 million to RMB 215 million for the year ended December 31, 2023, an increase of 49% to 67% compared to approximately RMB 129 million for the year ended December 31, 2022; and to obtain profit attributable to the company owners of approximately RMB approximately RMB 119 million for the year ended December 31, 2023.
PW Medtech Sees Up To 55% Profit Growth in 2023
PW Medtech Group (HKG:1358) expects an attributable profit of between 142 million yuan and 165 million yuan for 2023, marking a growth of 33% to 55% from 106 million yuan in 2022, a Wednesday filing o
PricewaterhouseCoopers (01358.HK) Yingxi: Net profit is expected to increase 33% to 55% in 2023
Gelonghui, March 13, 丨 PricewaterhouseCoopers (01358.HK) announced that the Group is expected to (i) record a net profit of between RMB 192 million and RMB 215 million for the year ended December 31, 2023, an increase of 49% to 67% compared to approximately RMB 129 million in 2022; and (ii) record profit attributable to the company's owners in 2023 of between RMB 142 million and RMB 165 million, an increase of 33% to 55% compared with approximately RMB 106 million in 2022. This increase is mainly due to the Group's blood purification business and infusion devices
PW MEDTECH: POSITIVE PROFIT ALERT
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Highlights of the morning brokerage meeting: Focus on opportunities to increase the localization rate of medical devices
At today's brokerage morning meeting, CICC believes that it is concerned about opportunities to increase the localization rate of medical devices; CITIC Construction Investment pointed out that the future of the cross-border e-commerce industry has great potential; and Guotai Junan said that it is concerned about undervalued consumption of blue-chip stocks.
Analysis
Price Target
No Data
